| |
 |
SYM |
Description |
|
|
Private |
Activity contingent weight-loss system developed in cooperation with Mayo Clinic |
 |
|
|
|
|
|
 |
|
private |
Medical device company developing obesity treatments. |
|
|
|
|
|
|
|
|
ETRM |
Medical devices to treat obesity and gastrointestinal disorders. |
|
|
|
|
|
|
|
|
Private |
Developing novel obesity device for nonsurgical treatment |
|
|
|
|
|
|
|
|
Private |
Treatment of human muscular degenerative diseases, as well as Type II diabetes and obesity. |
|
|
|
|
|
|
|
|
Private |
Medical device system for non-invasively treating obesity. |
|
|
|
|
|
|
|
|
Private |
Obesity Disease Management for the comprehensive, cost-effective treatment for obesity. |
|
|
|
|
|
|
|
|
Private |
Neuromodulation therapy for chronic obesity. |
|
|
|
|
|
|
|
|
Private |
Minimally invasive medical devices for the treatment of obesity.
|
|
|
|
|
|
|
|
|
Private |
Small molecule pharmaceuticals for obesity and its co-morbidities. |
|
|
|
|
|
|
|
|
Private |
Drugs for diabetes and obesity. |
|
|
|
|
|
|
|
|
Private |
Treatment of obesity and other metabolic diseases. |
|
|
|
|
|
|
|
|
Private |
Defining and validating drug compounds and target genes in obesity, diabetes, and similar fields. |
|
|
|
|
|
|
|
|
Private |
Drugs for obesity, hypercholesterolemia and type II diabetes. |
|
|
|
|
|
|
|
|
OREX |
Anti-obesity drug development. |
|
|
|
|
|
|
|
|
Private |
Services for biopharmaceutical companies developing drugs targeting diabetes and obesity. |
|
|
|
|
|
|
|
|
Private |
Products in the areas of anti-infectives, obesity and oncology. |
|
|
|
|
|
|
|
|
Private |
Therapies for metabolic disorders, such as obesity and diabetes. |
|
|
|
|
|
|
|
|
Private |
Drug discovery in the areas of pain and obesity. |
|
|
|
|
|
|
|
|
Private |
Endoscopically delivered gastric pacemaker for obesity treatment. |
|
|
|
|
|
|
|
|
Private |
Medical device company focused on nonsurgical, nonpharmacologic therapies for obesity. |
|
|
|
|
|
|
|
|
BVT |
Drug research with expertise in the fields of obesity, diabetes and inflammation. |
|
|
|
|
|
|
|
|
NRGN |
Small molecule drug candidates for pain, insomnia, inflammation, depression, and obesity. |
|
|
|
|
|
|
|
|
Private |
Develops treatments for obesity and other gastrointestinal disorders |
|
|
|
|
|
|
|
|
Private |
Drug discovery research. |
|
|
|
|
|
|
|
|
Private |
Solutions for medical aesthetics and obesity intervention. |
|
|
|
|
|
|
|
|
Private |
Discovers and develops novel therapeutics for the treatment of inflammatory and autoimmune diseases |
|
|
|
|
|
|
|
|
Private |
Unique therapies for the metabolic disease market. |
|
|
|
|
|
|
|
|
Private |
Drug targets and candidates in the areas of central nervous system disorders and metabolic disorders. |
|
|
|
|
|
|
|
|
Private |
Endoluminal procedures for the treatment of upper gastrointestinal diseases. |
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
OneMedPlace Member
